BURKE REHABILITATION HOSPITAL
CLINICAL TRIAL

For Individuals with Mild Cognitive Impairment or Mild Alzheimer’s Disease Dementia

BURKE is currently conducting a clinical trial to evaluate whether increasing brain glucose utilization can slow cognitive decline in individuals with Mild Cognitive Impairment or mild Alzheimer's disease dementia.

Thiamine (vitamin B1) is closely linked to glucose metabolism which is important to maintain memory and cognition. Many thiamine dependent processes are diminished in Alzheimer’s disease. Reduced glucose utilization is one of the early symptoms of Alzheimer’s disease.

The goal of this trial is to determine if increasing brain thiamine with the new investigational drug benfotiamine will minimize the decline in glucose utilization and slow the cognitive decline associated with Alzheimer’s disease.

Study participation will be over a 12 month period and will include follow-up visits to our clinic every 3 months. There are no costs associated with participation in this study.

This trial is being funded by the National Institutes of Health and The Alzheimer’s Drug Discovery Foundation.

For more information regarding this study, please contact Rosanna Cirio, MA at 914-597-2476 or rcirio@burke.org.

Individuals who are at least 60 years old and have a diagnosis of Cognitive Impairment or Mild Alzheimer’s disease may be eligible.

Study participants will receive:
• Neurological Exam
• Memory and Cognitive Testing
• Blood Work
• Neuro-Imaging

785 MAMARONECK AVENUE
WHITE PLAINS, NY 10605
888-99-BURKE
BURKE.ORG